Expertise in
39
conditions

Roberto Giugliani

Porto Alegre, RS, BR 
Expertise in
39
conditions
Porto Alegre, RS, BR 

Overview

Roberto Giugliani practices in Porto Alegre, Brazil. Mr. Giugliani is highly rated in 39 conditions, according to our data. His top areas of expertise are Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), Acid Sphingomyelinase Deficiency (ASMD), Mucopolysaccharidosis Type 7 (MPS VII, Sly Syndrome), and Bone Marrow Transplant.

His clinical research consists of co-authoring 379 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Male

Locations

Porto Alegre, RS, Brazil
Other Locations
Sao Paulo, SP 06455010, Brazil
Rio Grande, RS, Brazil
Brazil

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy
A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy
Enrollment Status: Active_not_recruiting
Publish Date: April 15, 2026
Intervention Type: Drug
Study Drug: SHP611
Study Phase: Phase 2
A Phase I/II Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Intracisternal RGX-111 Gene Therapy in Participants With Mucopolysaccharidosis Type I
A Phase I/II Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Intracisternal RGX-111 Gene Therapy in Participants With Mucopolysaccharidosis Type I
Enrollment Status: Suspended
Publish Date: March 12, 2026
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
Enrollment Status: Terminated
Publish Date: January 28, 2026
Intervention Type: Drug
Study Drug: Venglustat GZ402671
Study Phase: Phase 3
Natural History Study of Infantile and Juvenile GM1 Gangliosidosis (GM1) Patients
Natural History Study of Infantile and Juvenile GM1 Gangliosidosis (GM1) Patients
Enrollment Status: Completed
Publish Date: October 24, 2025
A Phase 1/2/3 Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of RGX-121 in Pediatric Subjects With MPS II (Hunter Syndrome)
A Phase 1/2/3 Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of RGX-121 in Pediatric Subjects With MPS II (Hunter Syndrome)
Enrollment Status: Active_not_recruiting
Publish Date: January 28, 2025
Intervention Type: Genetic
Study Phase: Phase 2/Phase 3
A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects With Fabry Disease
A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects With Fabry Disease
Enrollment Status: Terminated
Publish Date: June 17, 2024
Intervention Type: Drug
Study Drug: Replagal
Study Phase: Phase 3
Biomarker for Gilbert Disease - An International, Multi- Center, Epidemiological Protocol
Biomarker for Gilbert Disease - An International, Multi- Center, Epidemiological Protocol
Enrollment Status: Withdrawn
Publish Date: February 13, 2023
Biomarker for Niemann Pick Type C Disease (NPC1/NPC2) an International, Multicenter, Epidemiological Study
Biomarker for Niemann Pick Type C Disease (NPC1/NPC2) an International, Multicenter, Epidemiological Study
Enrollment Status: Withdrawn
Publish Date: February 13, 2023
Biomarkers for Hunter Syndrome: An International, Multicenter, Observational, Longitudinal Protocol
Biomarkers for Hunter Syndrome: An International, Multicenter, Observational, Longitudinal Protocol
Enrollment Status: Terminated
Publish Date: February 10, 2023
A Randomized Clinical Trial to Evaluate the Effects of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI
A Randomized Clinical Trial to Evaluate the Effects of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI
Enrollment Status: Unknown
Publish Date: December 19, 2022
Intervention Type: Drug
Study Drug: Losartan
Study Phase: Phase 2
View 9 Less Clinical Trials

379 Total Publications

The p.Ala1035Val variant in Niemann-Pick type C1: Clinical and molecular characterization in Brazilian and Portuguese patients suggests a shared founder effect.
The p.Ala1035Val variant in Niemann-Pick type C1: Clinical and molecular characterization in Brazilian and Portuguese patients suggests a shared founder effect.
Journal: Molecular genetics and metabolism
Published: January 29, 2026

Frequently Asked Questions about Roberto Giugliani

Is Roberto Giugliani a top-rated expert for Mucopolysaccharidoses (MPS)?

MediFind is an objective health platform that identifies experts based on real-world data. Roberto Giugliani is classified as an Elite expert for Mucopolysaccharidoses (MPS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Roberto Giugliani participate in research or clinical trials?

Yes. Roberto Giugliani has published 379 articles and abstracts on conditions like Mucopolysaccharidoses (MPS). You can view a list of Roberto Giugliani's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Giugliani's expertise for a condition
ConditionClose
View All 13 Elite Conditions
View All 7 Distinguished Conditions
View All 19 Advanced Conditions
View All 41 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile